Crossmark

Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL” (regional Tuscan lymphoma network)

Crossref DOI link: https://doi.org/10.1007/s00277-023-05113-9

Published Online: 2023-02-03

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cencini, Emanuele https://orcid.org/0000-0002-0432-9706
Romano, Ilaria

Ghio, Francesco

Camerini, Chiara

Bertaggia, Ilaria

Giachetti, Roberta

Mannelli, Lara

Pirrotta, Maria Teresa

Navei, Giulia Lucco

Ciceri, Manuel

Cervetti, Giulia

Sant’Antonio, Emanuela

Simonetti, Federico

Birtolo, Silvia

Puccini, Benedetta

Bocchia, Monica

Fabbri, Alberto
License Information

Text and Data Mining valid from 2023-02-03

Version of Record valid from 2023-02-03
More Information

Article History

Received: 26 September 2022

Accepted: 28 January 2023

First Online: 3 February 2023

Declarations

:

: This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of University of Siena approved this study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below